Compile Data Set for Download or QSAR
Report error Found 2376 Enz. Inhib. hit(s) with Target = 'Prolyl endopeptidase FAP'
TargetProlyl endopeptidase FAP(Mouse)
Philochem

US Patent
LigandPNGBDBM746820(US20250177582, Compound 28)
Affinity DataIC50: 0.00500nMAssay Description:Inhibition assay of FAP. The compounds were precisely weighed (range between 20-1000 pg) on a micro-scale (HuberLab, Sartorius QUINTIX35-1S) and diss...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/30/2025
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622261(US20230312550, Example 221)
Affinity DataKd:  0.00500nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622083(US20230312550, Example 43)
Affinity DataKd:  0.00600nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622115(US20230312550, Example 75)
Affinity DataKd:  0.00600nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622232(US20230312550, Example 192)
Affinity DataKd:  0.00800nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622189(US20230312550, Example 149)
Affinity DataKd:  0.00900nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622064(US20230312550, Example 24)
Affinity DataKd:  0.00900nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622138(US20230312550, Example 98)
Affinity DataKd:  0.00900nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622263(US20230312550, Example 223)
Affinity DataKd:  0.0100nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622268(US20230312550, Example 229)
Affinity DataKd:  0.0100nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622228(US20230312550, Example 188)
Affinity DataKd:  0.0110nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622247(US20230312550, Example 207)
Affinity DataKd:  0.0110nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622107(US20230312550, Example 109 | US20230312550, Exampl...)
Affinity DataKd:  0.0120nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622161(US20230312550, Example 121)
Affinity DataKd:  0.0120nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622175(US20230312550, Example 135)
Affinity DataKd:  0.0130nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622192(US20230312550, Example 152)
Affinity DataKd:  0.0130nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622177(US20230312550, Example 137)
Affinity DataKd:  0.0130nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622117(US20230312550, Example 77)
Affinity DataKd:  0.0140nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622053(US20230312550, Example 13)
Affinity DataKd:  0.0140nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622224(US20230312550, Example 184)
Affinity DataKd:  0.0150nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622057(US20230312550, Example 17)
Affinity DataKd:  0.0150nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622179(US20230312550, Example 139)
Affinity DataKd:  0.0150nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622193(US20230312550, Example 153)
Affinity DataKd:  0.0150nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622195(US20230312550, Example 155)
Affinity DataKd:  0.0160nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622098(US20230312550, Example 58)
Affinity DataKd:  0.0160nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622210(US20230312550, Example 170)
Affinity DataKd:  0.0170nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622119(US20230312550, Example 79)
Affinity DataKd:  0.0180nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622202(US20230312550, Example 162)
Affinity DataKd:  0.0180nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622150(US20230312550, Example 110)
Affinity DataKd:  0.0190nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622230(US20230312550, Example 190)
Affinity DataKd:  0.0200nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622086(US20230312550, Example 46)
Affinity DataKd:  0.0200nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622089(US20230312550, Example 49)
Affinity DataKd:  0.0200nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622249(US20230312550, Example 209)
Affinity DataKd:  0.0200nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622229(US20230312550, Example 189)
Affinity DataKd:  0.0200nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622144(US20230312550, Example 104)
Affinity DataKd:  0.0200nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622091(US20230312550, Example 51)
Affinity DataKd:  0.0210nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622231(US20230312550, Example 191)
Affinity DataKd:  0.0220nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622072(US20230312550, Example 32)
Affinity DataKd:  0.0220nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622262(US20230312550, Example 222)
Affinity DataKd:  0.0220nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622110(US20230312550, Example 70)
Affinity DataKd:  0.0220nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622097(US20230312550, Example 57)
Affinity DataKd:  0.0220nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622201(US20230312550, Example 161)
Affinity DataKd:  0.0220nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622264(US20230312550, Example 224)
Affinity DataKd:  0.0230nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622067(US20230312550, Example 27)
Affinity DataKd:  0.0240nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622135(US20230312550, Example 95)
Affinity DataKd:  0.0240nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM50434166(CHEMBL2385270 | US9346814, Cmpd No 6 Example 9 | U...)
Affinity DataKi:  0.0240nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2025
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622241(US20230312550, Example 201)
Affinity DataIC50: 0.0250nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622250(US20230312550, Example 210)
Affinity DataKd:  0.0260nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622245(US20230312550, Example 205)
Affinity DataKd:  0.0260nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622112(US20230312550, Example 72)
Affinity DataKd:  0.0260nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Displayed 1 to 50 (of 2376 total ) | Next | Last >>
Jump to: